Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000807098> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2000807098 endingPage "6" @default.
- W2000807098 startingPage "1" @default.
- W2000807098 abstract "Summary. Immune tolerance therapy (ITT) is currently the most effective approach to eradicate inhibitors in patients with haemophilia A. Limited evidence suggests that the use of plasma‐derived factor VIII (pdFVIII) for ITT may be associated with a greater success rate than recombinant factor VIII (rFVIII). Analysis of ITT cases in Canada offered the opportunity to examine the success rate of using rFVIII for ITT, as rFVIII has been used almost exclusively for Canadian haemophilia A patients since 1994. The results of 32 patients from five haemophilia treatment centres were collated. Three patients continue on ITT. Of the 29 patients who completed ITT, 25 (86.2%) used rFVIII exclusively, and four used pdFVIII exclusively or pdFVIII followed by rFVIII. The initial FVIII dosing frequency was once per day in 72.4% of patients at an average dose of 98 U kg −1 (range 50–200). Eight patients (25%) received one or more adjuvant therapies. The median duration of ITT was 1.1 years (mean 1.5 years, range 9 days to 6 years). The overall success rate of the 29 patients who completed ITT was 79.3% (23/29), which is comparable with the results of immune tolerance registries. Our results suggest that the success rate of ITT using rFVIII is not inferior to the results with pdFVIII." @default.
- W2000807098 created "2016-06-24" @default.
- W2000807098 creator A5002660666 @default.
- W2000807098 creator A5013380555 @default.
- W2000807098 creator A5014215337 @default.
- W2000807098 creator A5022397589 @default.
- W2000807098 creator A5050252054 @default.
- W2000807098 creator A5062437339 @default.
- W2000807098 creator A5069488134 @default.
- W2000807098 creator A5081951778 @default.
- W2000807098 date "2005-11-08" @default.
- W2000807098 modified "2023-10-15" @default.
- W2000807098 title "Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT" @default.
- W2000807098 cites W1921219324 @default.
- W2000807098 cites W1968617043 @default.
- W2000807098 cites W1997284311 @default.
- W2000807098 cites W1999636421 @default.
- W2000807098 cites W2008060999 @default.
- W2000807098 cites W2017919788 @default.
- W2000807098 cites W2037201482 @default.
- W2000807098 cites W2042478977 @default.
- W2000807098 cites W2042508808 @default.
- W2000807098 cites W2056634959 @default.
- W2000807098 cites W2064506335 @default.
- W2000807098 cites W2166739970 @default.
- W2000807098 cites W2415139732 @default.
- W2000807098 cites W2417605240 @default.
- W2000807098 cites W2589655284 @default.
- W2000807098 doi "https://doi.org/10.1111/j.1365-2516.2005.01167.x" @default.
- W2000807098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16409169" @default.
- W2000807098 hasPublicationYear "2005" @default.
- W2000807098 type Work @default.
- W2000807098 sameAs 2000807098 @default.
- W2000807098 citedByCount "36" @default.
- W2000807098 countsByYear W20008070982012 @default.
- W2000807098 countsByYear W20008070982013 @default.
- W2000807098 countsByYear W20008070982014 @default.
- W2000807098 countsByYear W20008070982015 @default.
- W2000807098 countsByYear W20008070982016 @default.
- W2000807098 countsByYear W20008070982018 @default.
- W2000807098 countsByYear W20008070982022 @default.
- W2000807098 countsByYear W20008070982023 @default.
- W2000807098 crossrefType "journal-article" @default.
- W2000807098 hasAuthorship W2000807098A5002660666 @default.
- W2000807098 hasAuthorship W2000807098A5013380555 @default.
- W2000807098 hasAuthorship W2000807098A5014215337 @default.
- W2000807098 hasAuthorship W2000807098A5022397589 @default.
- W2000807098 hasAuthorship W2000807098A5050252054 @default.
- W2000807098 hasAuthorship W2000807098A5062437339 @default.
- W2000807098 hasAuthorship W2000807098A5069488134 @default.
- W2000807098 hasAuthorship W2000807098A5081951778 @default.
- W2000807098 hasConcept C126322002 @default.
- W2000807098 hasConcept C141071460 @default.
- W2000807098 hasConcept C2777232031 @default.
- W2000807098 hasConcept C2777288759 @default.
- W2000807098 hasConcept C2778385053 @default.
- W2000807098 hasConcept C71924100 @default.
- W2000807098 hasConceptScore W2000807098C126322002 @default.
- W2000807098 hasConceptScore W2000807098C141071460 @default.
- W2000807098 hasConceptScore W2000807098C2777232031 @default.
- W2000807098 hasConceptScore W2000807098C2777288759 @default.
- W2000807098 hasConceptScore W2000807098C2778385053 @default.
- W2000807098 hasConceptScore W2000807098C71924100 @default.
- W2000807098 hasIssue "1" @default.
- W2000807098 hasLocation W20008070981 @default.
- W2000807098 hasLocation W20008070982 @default.
- W2000807098 hasOpenAccess W2000807098 @default.
- W2000807098 hasPrimaryLocation W20008070981 @default.
- W2000807098 hasRelatedWork W1995822104 @default.
- W2000807098 hasRelatedWork W2005719195 @default.
- W2000807098 hasRelatedWork W2067082011 @default.
- W2000807098 hasRelatedWork W2086676349 @default.
- W2000807098 hasRelatedWork W2101928171 @default.
- W2000807098 hasRelatedWork W2166990743 @default.
- W2000807098 hasRelatedWork W3113163854 @default.
- W2000807098 hasRelatedWork W3155450815 @default.
- W2000807098 hasRelatedWork W4233505807 @default.
- W2000807098 hasRelatedWork W4292525692 @default.
- W2000807098 hasVolume "12" @default.
- W2000807098 isParatext "false" @default.
- W2000807098 isRetracted "false" @default.
- W2000807098 magId "2000807098" @default.
- W2000807098 workType "article" @default.